GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GATC Biotech has announced the purchase of Illumina’s new HiSeq 2000 sequencing platform, which has officially been launched last week. This latest acquisition will further strengthen GATC Biotech’s current fleet of three GA IIx.
Initially, the company will employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It will also make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.
“Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production,” says Peter Pohl, CEO of GATC Biotech.
The HiSeq 2000 sequencing system had just been launched by llumina Inc. on the occasion of the J.P. Morgan Healthcare Conference last week in San Diego.
Initially, the company will employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It will also make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.
“Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production,” says Peter Pohl, CEO of GATC Biotech.
The HiSeq 2000 sequencing system had just been launched by llumina Inc. on the occasion of the J.P. Morgan Healthcare Conference last week in San Diego.
